Immutep Limited (IMM, Prima BioMed Ltd) is a biotechnology company headquarters in Australia. IMM focuses on personalised bio-therapeutic products for cancer. Its main products are eftilagimod alpha (“Efti” or ” IMP321″), a soluble LAG-3Ig fusion protein, which is in clinical development for the treatment of cancer. Immutep has two other clinical candidates (IMP701 and IMP731) that are fully licensed to major pharmaceutical partners, and a fourth candidate (IMP761) which is in pre-clinical development.
Immutep Limited operators in Health Care sector and under industry of Biotechnology. The company website is: http://www.immutep.com.
You can also check out dividend history for similar stocks in the same sector as follows:
IMM Dividend Dates
Please click the table header to sort the data.
No Dividend Dates Found